House committees kick off investigation into how Biogen's Aduhelm won approval

Two key House committees — on Oversight and Reform, and Energy and Commerce — have now officially opened their own investigation into the approval of Biogen’s new Alzheimer’s drug Aduhelm by asking the company for a variety of different internal and external documents and communications relating to assessments of the drug’s safety, efficacy, or clinical benefit.